These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 25605840)

  • 21. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study.
    Quaglino P; Marenco F; Osella-Abate S; Cappello N; Ortoncelli M; Salomone B; Fierro MT; Savoia P; Bernengo MG
    Ann Oncol; 2010 Feb; 21(2):409-414. PubMed ID: 19622589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melanoma and Vitiligo: In Good Company.
    Failla CM; Carbone ML; Fortes C; Pagnanelli G; D'Atri S
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
    Chick RC; Faries MB; Hale DF; Kemp Bohan PM; Hickerson AT; Vreeland TJ; Myers JW; Cindass JL; Brown TA; Hyngstrom J; Berger AC; Jakub JW; Sussman JJ; Shaheen M; Clifton GT; Park H; Sloan AJ; Wagner T; Peoples GE
    Cancer Med; 2021 Jul; 10(13):4302-4311. PubMed ID: 33982452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity.
    van den Boorn JG; Melief CJ; Luiten RM
    Pigment Cell Melanoma Res; 2011 Aug; 24(4):673-9. PubMed ID: 21689385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccines for melanoma.
    Bystryn JC
    Dermatol Clin; 2002 Oct; 20(4):717-25. PubMed ID: 12380059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut microbiome and immunotherapy response.
    Burki TK
    Lancet Oncol; 2017 Dec; 18(12):e717. PubMed ID: 29129446
    [No Abstract]   [Full Text] [Related]  

  • 27. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
    Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
    J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disparities of Immunotherapy Utilization in Patients with Stage III Cutaneous Melanoma: A National Perspective.
    Al-Qurayshi Z; Crowther JE; Hamner JB; Ducoin C; Killackey MT; Kandil E
    Anticancer Res; 2018 May; 38(5):2897-2901. PubMed ID: 29715114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic score for patients with advanced melanoma treated with ipilimumab.
    Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
    Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved Survival with Immunotherapy but Lack of Synergistic Effect with Radiation for Stage IV Melanoma of the Head and Neck.
    Babcock B; Rodrigues M; Kearns D; Solomon N; Reeves ME; Senthil M; Garberoglio CA; Namm JP
    Am Surg; 2019 Oct; 85(10):1118-1124. PubMed ID: 31657306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.
    Melief SM; Visconti VV; Visser M; van Diepen M; Kapiteijn EH; van den Berg JH; Haanen JB; Smit VT; Oosting J; van der Burg SH; Verdegaal EM
    Cancer Immunol Res; 2017 Feb; 5(2):170-179. PubMed ID: 28073773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial.
    Hersey P; Coates AS; McCarthy WH; Thompson JF; Sillar RW; McLeod R; Gill PG; Coventry BJ; McMullen A; Dillon H; Simes RJ
    J Clin Oncol; 2002 Oct; 20(20):4181-90. PubMed ID: 12377961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical management of stage IV malignant melanoma. Medical issues.
    Ho RC
    Cancer; 1995 Jan; 75(2 Suppl):735-41. PubMed ID: 7805002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma: A Retrospective Study of Primary Tumor Characteristics.
    Luen S; Wong SW; Mar V; Kelly JW; McLean C; McArthur GA; Haydon A
    Am J Clin Oncol; 2018 Jan; 41(1):90-94. PubMed ID: 26325493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
    Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
    Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is sex an independent prognostic factor in cutaneous head and neck melanoma?
    Arce PM; Camilon PR; Stokes WA; Nguyen SA; Lentsch EJ
    Laryngoscope; 2014 Jun; 124(6):1363-7. PubMed ID: 24122966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ipilimumab in advanced melanoma: reports of long-lasting responses.
    Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
    Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metastatic malignant melanoma associated with vitiligo-like depigmentation.
    Wang JR; Yu KJ; Juan WH; Yang CH
    Clin Exp Dermatol; 2009 Mar; 34(2):209-11. PubMed ID: 18691245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo.
    Fishman P; Merimski O; Baharav E; Shoenfeld Y
    Cancer; 1997 Apr; 79(8):1461-4. PubMed ID: 9118024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.